Program
4CMenB vaccine
Also written as “rLP2086”, “rMenB+OMV NZ” and “Meningococcal B vaccine”.
In GlaxoSmithKline’s pipeline, Recombinant protein and outer membrance vesicle vaccine
. Its studies are mostly in Meningococcal Infections · Meningitis, Meningococcal · Meningitis · Anemia, Sickle Cell, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 130 open or running | phase 3since Apr 2, 2008 | Feb 27, 2006 | none ahead |
| Pfizerits history only | 90 open or running | phase 4since May 14, 2021 | Oct 11, 2006 | none ahead |
| GlaxoSmithKlineits history only | 71 open or running | phase 4since Feb 6, 2018 | Feb 14, 2014 | none ahead |
| Sanofiits history only | 20 open or running | phase 3since Sep 4, 2019 | Sep 4, 2019 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
Men B vaccine GSK3536829
, phase 3, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2006First study: phase 2 study in Meningococcal InfectionsFirst studyNCT00297817 · 203 enrolled · United States
- Apr 2, 20082 phase 3 studiesNCT00657709, NCT00661713
- Jul 22, 2008Phase 2 study in Meningococcal InfectionsNCT00721396 · 1,885 enrolled · Belgium, Czech Republic, Germany and more
- Jun 29, 2009Phase 2 study in Meningitis, MeningococcalNCT00937521 · 1,507 enrolled · Argentina, Chile, Czech Republic and more
- Jul 21, 2009Phase 3 study in Meningococcal InfectionsNCT00944034 · 1,588 enrolled · Belgium, Czechia, Germany and more
- Dec 4, 2009Phase 2 study in Meningococcal InfectionsNCT01026974 · 120 enrolled · United Kingdom
- Jun 4, 2010Phase 3 study in Meningococcal InfectionsNCT01139021 · 508 enrolled · Czech Republic, Finland
- Sep 30, 2010Phase 3 study in N. Meningitidis CarriageNCT01214850 · 2,968 enrolled · United Kingdom
- Aug 23, 2011Phase 3 study in Meningococcal InfectionsNCT01423084 · 344 enrolled · Australia, Canada
- Oct 18, 2012Phase 3 study in Meningococcal InfectionsNCT01717638 · 805 enrolled · Czech Republic, Italy, Spain and more
- Jul 26, 2013Phase 3 study in Meningococcal InfectionsNCT01911221 · 13 enrolled · Germany
- Nov 20, 2014Phase 3 study in Meningitis, MeningococcalNCT02305446 · 55 enrolled · Poland
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Recombinant protein and outer membrance vesicle vaccine”the company's pipeline, read by Claude · source
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal gr…”NCIt, read by Claude
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group”NCIt, by rule
Studies
All 13 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02305446Meningitis, Meningococcal · Poland | 3 | Completed | Apr 2015 | 55 |
| NCT01911221Meningococcal Infections · Germany | 3 | Completed | Apr 2014 | 13 |
| NCT01717638Meningococcal Infections · Czech Republic, Italy, Spain and more | 3 | Completed | Sep 2013 | 805 |
| NCT01423084Meningococcal Infections · Australia, Canada | 3 | Completed | Dec 2011 | 344 |
| NCT01214850N. Meningitidis Carriage · United Kingdom | 3 | Completed | Jan 2012 | 2,968 |
| NCT01139021Meningococcal Infections · Czech Republic, Finland | 3 | Completed | Nov 2010 | 508 |
| NCT01026974Meningococcal Infections · United Kingdom | 2 | Completed | Sep 2010 | 120 |
| NCT00944034Meningococcal Infections · Belgium, Czechia, Germany and more | 3 | Completed | Aug 2011 | 1,588 |
| NCT00937521Meningitis, Meningococcal · Argentina, Chile, Czech Republic and more | 2 | Completed | Nov 2010 | 1,507 |
| NCT00721396Meningococcal Infections · Belgium, Czech Republic, Germany and more | 2 | Completed | Jul 2010 | 1,885 |
| NCT00661713Meningococcal Infections · Chile | 3 | Completed | Apr 2010 | 1,631 |
| NCT00657709Meningitis, Meningococcal · Austria, Czechia, Finland and more | 3 | Completed | Jan 2010 | 3,630 |
| NCT00297817Meningococcal Infections · United States | 2 | Completed | Apr 2007 | 203 |
How it is read
Names in the registry
- “rLP2086”, 11 entries
- “rMenB+OMV NZ”, 9 entries
- “Meningococcal B vaccine”, 6 entries
- “rMenB+OMV NZ vaccine”, 3 entries
- “Meningococcal group B vaccine”, 3 entries
Conditions, from the studies’ own filings
- Meningococcal Infections, 10 studies
- Meningitis, Meningococcal, 9 studies
- Meningitis, 2 studies
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.